Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
Amgen secured victory yesterday as a US federal judge refused to throw out a ruling upholding the validity of two patents owned by the company.   4 January 2017
Americas
Intellectual property law firm Fitzpatrick, Cella, Harper & Scinto has appointed Susanne Flanders, Natalie Lieber and Dennis McMahon as partners in the firm.   4 January 2017
Americas
Healthcare company Abbott Laboratories has agreed to divest two medical device businesses in a bid to settle competition charges brought by the US Federal Trade Commission.   3 January 2017
Americas
Sanofi, and its subsidiary Genzyme, has targeted two pharmaceutical companies in patent lawsuits related to its drug Aubagio.   3 January 2017
Big Pharma
It appears necessary and perhaps inevitable that further guidance from the UK Court of Appeal will be provided on the issue of second medical use patents, following the high-profile dispute between Warner-Lambert and Actavis. Geoff Hussey and Christopher Burnett of AA Thornton & Co report.   3 January 2017
Asia-Pacific
A report released by the Australian government has said Australia's extension of term scheme for patents in the pharmaceutical industry "has had little effect" on investment and innovation.   23 December 2016
Big Pharma
Teva has filed a complaint against nine pharmaceutical companies including Dr Reddy's Laboratories, Sandoz and Mylan for alleged patent infringement over Copaxone, a treatment for patients with multiple sclerosis.   23 December 2016
Americas
Pfizer has agreed a collaboration and licensing agreement with Sweden-based pharmaceutical company BioInvent International on cancer immunotherapy research.   22 December 2016
Americas
Millennium Pharmaceuticals, now known as Takeda Oncology, has filed a complaint against US-based MSN Laboratories for patent infringement of Velcade, a treatment for cancer.   22 December 2016
Big Pharma
A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains.   22 December 2016